Senior Manager

Location(s): Munich, Germany

Level of position: Senior Manager

Position type: Office-based, in alignment with BlueFlex model*

Reporting Line: Senior Director, P&MA Lead DACH, Nordic Countries

How will your role help us transform hope into reality?

The Senior Manager Market Access & Corporate Affairs Germany will manage Pricing & Market Access (PMA) for AYVAKYT (avapritinib) in indolent and advanced systemic mastocytosis as well as plan and execute communication & PR and Patient Affairs & Governmental Affairs activities. The purpose is to identify the needs of patients, healthcare providers and payers in Germany and address challenges and opportunities to maximize access, communicate with stakeholders and contribute to BPMs success. Analyze and assess market access insights, develop strategies and solutions for implementation is key with this role.

What will you do?

• Support with HTA (AMNOG) assessment procedure including written statement and oral hearing;
• Develop materials for payer engagement initiatives;
• Support price negotiations with pricing analysis, pricing intelligence and HEOR initiatives;
• Manage regional and local hurdles and opportunities with Avapritinib and support field teams;
• Develop and execute the PR/communication plan aligned with brand strategy;
• Analyze and assess Governmental regulations on national and local level with impact for BPM and develop recommendations to strengthen BPM business;
• Engage with patient organizations and present BPM as partner in systemic mastocytosis.

What minimum qualifications do we require?

• Academic education and experience from similar positions (life science, economics, media)
• Minimum of 5+ years’ experience in pharmaceutical/biotechnology field
• Strong knowledge of Market Access and HTA/Payer requirements, standards and processes, including experience with national and regional authorities, including sick funds and other payers
• Experience with communications and PR initiatives
• Experience to manage complex projects and colaborate with multi-disciplinary teams
• Commitment to our Core Values: Patients First, Thoughtfulness, Urgency, Trust, Optimism

What additional qualifications will make you a stronger candidate?

• Ability to lead PMA initiatives and work as part of a team under uncertainty with a “can do” attitude
• Ability to prioritize and drive for results with an emphasis on quality.
• Ability to analyze diverse sets of complex information and distill into recommended strategy
• Computer skills (MS Office programs)
• Fluency in German and English, both oral and written
• Effective communication skills at all levels both internally and externally
• In-depth understanding of health insurance systems such as reimbursement pathways, HTA and contracting opportunities

Why Blueprint? 

At Blueprint Medicines, we achieve impactful results because of our global crew of compassionate innovators – the Blue Crew. Through authentic relationships and our collective entrepreneurial spirit and action, we are each empowered to take ownership and execute with strategic prioritization. We put trust in our people to break through norms and conventions using their individual strengths and insights, which drives our success.

This is the place where the extraordinary becomes reality, and you could be part of it. Patients are waiting.

Are you ready to make the leap?

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a proven track record of success with two approved medicines, including bringing our medicine to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. As of July 17th2025 Blueprint Medicines is a Sanofi company.

*Blueflex is our operating model which optimizes culture, productivity, & flexibility by maximizing the critical strengths of in-person work with the benefits of added flexibility.  Blueflex allows for mix of in-office and remote work, enables flexibility to meet individual and business needs and makes effective use of our facilities and resources.  It is a culture enhancer.